Results on July 22, and Analysts/Investors Meeting
Results on July 22: Hindustan Unilever, UltraTech Cement, Bajaj Auto, Agro Tech Foods, Bajaj Holdings & Investment, Biocon, Can Fin Homes, Chennai Petroleum Corporation, CSB Bank, Heidelbergcement India, Hindustan Zinc, ICICI Lombard General Insurance Company, Indian Energy Exchange, IIFL Securities, IndiaMART InterMESH, India Pesticides, Lloyds Steels Industries, Bank of Maharashtra, Mahindra EPC Irrigation, Mphasis, Persistent Systems, Music Broadcast, Shiva Cement, South Indian Bank, Sterlite Technologies, and Wockhardt will release their quarterly earnings on July 22.
South Indian Bank: The company's officials will meet analysts and investors on July 23 in respect of unaudited financial results.
GE T&D India: The company's officials will meet analysts and investors on July 23.
HeidelbergCement India: The company's officials will meet analysts and institutional investors on July 23 to discuss unaudited financial results.
Motilal Oswal Financial Services: The company's officials will meet investors and analysts on July 30 to discuss financial performance.
Godrej Properties: The company's officials will meet investors and analysts on August 3.
Stocks in News
Network18 Media & Investments: The company reported sharp increase in consolidated operating revenue at Rs 1,214 crore for Q1FY22 against Rs 807 crore in Q1FY21. Operating EBITDA jumped to Rs 188 crore from Rs 27 crore YoY
TV18 Broadcast: The company's consolidated operating revenue for Q1FY22 came in at Rs 1,155 crore against Rs 776 crore in Q1FY21, operating EBITDA jumped to Rs 188 crore from Rs 44 crore YoY.
Jubilant Ingrevia: East Bridge Capital Master Fund sold 2.4% stake in the company via open market transaction on July 19, reducing shareholding to 5.61% from 8% earlier.
IDFC First Bank: The RBI said IDFC can exit as promoter of IDFC FIRST Bank after the expiry of lock-in period of 5 years. IDFC holds 36.56% in IDFC First Bank.
Havells India: The company reported consolidated profit of Rs 235.78 crore in Q1FY22 against Rs 63.98 crore in Q1FY21, revenue rose to Rs 2,609.97 crore from Rs 1,483.40 crore YoY.
Gland Pharma: The company reported higher consolidated profit at Rs 350.65 crore in Q1FY22 against Rs 313.59 crore in Q1FY21, revenue rose to Rs 1,153.9 crore from Rs 884.2 crore YoY.